Printed:
Novo Nordisk’s inventory plunged Tuesday after the maker of diabetes and weight-loss medication Ozempic and Wegovy mentioned it expects gross sales to fall by much more than analysts had been projecting.
In a shock transfer, the Danish drugmaker NGOs introduced its fourth-quarter outcomes a day early. Throughout the outcomes, the corporate mentioned it expects 2026 adjusted gross sales development, which excludes sure nonrecurring gadgets, to fall by 5% to 13% from 2025 ranges. That got here as a shock to traders, as the present common analyst estimate compiled by FactSet for 2026 gross sales implies only a 3.5% decline.